 Lentiviral Vector Market Size, Share & Trends Analysis Report By Product (1st-Generation, 2nd-Generation, 3rd-Generation), By Indication (HIV, -Thalassemia), By End Use (Academic and Research Institute, CROs & CMOs), By Region, And Segment Forecasts, 2026 - 2033
Lentiviral Vector Market Summary The global lentiviral vector market size was valued at USD 601.1 million in 2025 and is projected to reach USD 1,140.6 million by 2033, growing at a CAGR of 8.4... もっと見る
英語原文をAIを使って翻訳しています。
SummaryLentiviral Vector Market SummaryThe global lentiviral vector market size was valued at USD 601.1 million in 2025 and is projected to reach USD 1,140.6 million by 2033, growing at a CAGR of 8.4% from 2026 to 2033. Growth is driven by rising demand for gene and cell therapies, increasing clinical research, and advancements in vector manufacturing. However, high costs and regulatory complexities may hinder market expansion. Global Lentiviral Vector Market Report Segmentation This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the global lentiviral vector market report on the basis of product, indication, end use, and region. • Product Outlook (Revenue, USD Million, 2021 - 2033) • 1st-Generation • 2nd-Generation • 3rd-Generation • Indication Outlook (Revenue, USD Million, 2021 - 2033) • HIV • Β-Thalassemia • X-Linked Adrenoleukodystrophy • Metachromatic Leukodystrophy • Wiskott-Aldrich Syndrome • End Use Outlook (Revenue, USD Million, 2021 - 2033) • Pharmaceutical and Biotechnology Companies • Academic & Research Institutes • CROs & CMOs • Regional Outlook (Revenue, USD Million, 2021 - 2033) • North America o U.S. o Canada o Mexico • Europe o Germany o UK o France o Italy o Spain o Denmark o Sweden o Norway • Asia Pacific o China o Japan o India o South Korea o Australia o Thailand • Latin America o Brazil o Argentina • MEA o South Africa o Saudi Arabia o UAE o Kuwait Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definitions 1.2.1. Product Segment 1.2.2. Indication Segment 1.2.3. End Use Segment 1.3. Information analysis 1.3.1. Market formulation & data visualization 1.4. Data validation & publishing 1.5. Information Procurement 1.5.1. Primary Research 1.6. Information or Data Analysis 1.7. Market Formulation & Validation 1.8. Market Model 1.9. Objectives Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Snapshot 2.3. Competitive Landscape Snapshot Chapter 3. Lentiviral Vector Market Variables, Trends & Scope 3.1. Market Lineage Outlook 3.1.1. Parent market outlook 3.1.2. Related/ancillary market outlook. 3.2. Market Dynamics 3.2.1. Market driver analysis 3.2.1.1. Growth of CAR-T and advanced immunotherapies 3.2.1.2. Technological advancements in vector design 3.2.1.3. Improved safety and efficiency of next-generation vectors 3.2.1.4. Growing investment in biomanufacturing and CDMO capacity 3.2.2. Market restraint analysis 3.2.2.1. High production costs and scalability challenges 3.2.2.2. Stringent regulatory requirements 3.2.3. Market opportunity analysis 3.2.4. Market challenge analysis 3.3. Case Study Insights 3.4. Lentiviral Vector Market Analysis Tools 3.4.1. Industry Analysis - Porter’s 3.4.2. PESTEL Analysis Chapter 4. Lentiviral Vector Market: Product Estimates & Trend Analysis 4.1. Segment Dashboard 4.2. Global Lentiviral Vector Market Product Movement Analysis 4.3. Global Lentiviral Vector Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million) 4.4. 1st-Generation 4.4.1. 1st-generation market estimates and forecasts 2021 to 2033 (USD Million) 4.5. 2nd-Generation 4.5.1. 2nd-generation market estimates and forecasts 2021 to 2033 (USD Million) 4.6. 3rd-Generation 4.6.1. 3rd-generation market estimates and forecasts 2021 to 2033 (USD Million) Chapter 5. Lentiviral Vector Market: Indication Estimates & Trend Analysis 5.1. Segment Dashboard 5.2. Global Lentiviral Vector Market Indication Movement Analysis 5.3. Global Lentiviral Vector Market Size & Trend Analysis, by Indication, 2021 to 2033 (USD Million) 5.4. HIV 5.4.1. HIV market estimates and forecasts 2021 to 2033 (USD Million) 5.5. Β-Thalassemia 5.5.1. Β-thalassemia market estimates and forecasts 2021 to 2033 (USD Million) 5.6. X-Linked Adrenoleukodystrophy 5.6.1. X-Linked adrenoleukodystrophy market estimates and forecasts 2021 to 2033 (USD Million) 5.7. Metachromatic Leukodystrophy 5.7.1. Metachromatic leukodystrophy market estimates and forecasts 2021 to 2033 (USD Million) 5.8. Wiskott-Aldrich Syndrome 5.8.1. Wiskott-aldrich syndrome market estimates and forecasts 2021 to 2033 (USD Million) Chapter 6. Lentiviral Vector Market: End Use Estimates & Trend Analysis 6.1. Segment Dashboard 6.2. Global Lentiviral Vector Market End Use Movement Analysis 6.3. Global Lentiviral Vector Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million) 6.4. Pharmaceutical and Biotechnology Companies 6.4.1. Pharmaceutical and biotechnology companies market estimates and forecasts 2021 to 2033 (USD Million) 6.5. Academic & Research Institutes 6.5.1. Academic & research institutes market estimates and forecasts 2021 to 2033 (USD Million) 6.6. CROs & CMOs 6.6.1. CROs & CMOs market estimates and forecasts 2021 to 2033 (USD Million) Chapter 7. Lentiviral Vector Market: Regional Estimates & Trend Analysis 7.1. Regional Market Share Analysis, 2025 & 2033 7.2. Regional Market Dashboard 7.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033: 7.4. North America 7.4.1. Market estimates and forecasts 2021 to 2033 (USD Million) 7.4.2. U.S. 7.4.2.1. Key country dynamics 7.4.2.2. Competitive scenario 7.4.2.3. Regulatory framework 7.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million) 7.4.3. Canada 7.4.3.1. Key country dynamics 7.4.3.2. Competitive scenario 7.4.3.3. Regulatory framework 7.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million) 7.4.4. Mexico 7.4.4.1. Key country dynamics 7.4.4.2. Competitive scenario 7.4.4.3. Regulatory framework 7.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million) 7.5. Europe 7.5.1. Market estimates and forecasts 2021 to 2033 (USD Million) 7.5.2. UK 7.5.2.1. Key country dynamics 7.5.2.2. Competitive scenario 7.5.2.3. Regulatory framework 7.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million) 7.5.3. Germany 7.5.3.1. Key country dynamics 7.5.3.2. Competitive scenario 7.5.3.3. Regulatory framework 7.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million) 7.5.4. France 7.5.4.1. Key country dynamics 7.5.4.2. Competitive scenario 7.5.4.3. Regulatory framework 7.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million) 7.5.5. Italy 7.5.5.1. Key country dynamics 7.5.5.2. Competitive scenario 7.5.5.3. Regulatory framework 7.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million) 7.5.6. Spain 7.5.6.1. Key country dynamics 7.5.6.2. Competitive scenario 7.5.6.3. Regulatory framework 7.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million) 7.5.7. Norway 7.5.7.1. Key country dynamics 7.5.7.2. Competitive scenario 7.5.7.3. Regulatory framework 7.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million) 7.5.8. Sweden 7.5.8.1. Key country dynamics 7.5.8.2. Competitive scenario 7.5.8.3. Regulatory framework 7.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million) 7.5.9. Denmark 7.5.9.1. Key country dynamics 7.5.9.2. Competitive scenario 7.5.9.3. Regulatory framework 7.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million) 7.6. Asia Pacific 7.6.1. Market estimates and forecasts 2021 to 2033 (USD Million) 7.6.2. Japan 7.6.2.1. Key country dynamics 7.6.2.2. Competitive scenario 7.6.2.3. Regulatory framework 7.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million) 7.6.3. China 7.6.3.1. Key country dynamics 7.6.3.2. Competitive scenario 7.6.3.3. Regulatory framework 7.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million) 7.6.4. India 7.6.4.1. Key country dynamics 7.6.4.2. Competitive scenario 7.6.4.3. Regulatory framework 7.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million) 7.6.5. Australia 7.6.5.1. Key country dynamics 7.6.5.2. Competitive scenario 7.6.5.3. Regulatory framework 7.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million) 7.6.6. South Korea 7.6.6.1. Key country dynamics 7.6.6.2. Competitive scenario 7.6.6.3. Regulatory framework 7.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million) 7.6.7. Thailand 7.6.7.1. Key country dynamics 7.6.7.2. Competitive scenario 7.6.7.3. Regulatory framework 7.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million) 7.7. Latin America 7.7.1. Market estimates and forecasts 2021 to 2033 (USD Million) 7.7.2. Brazil 7.7.2.1. Key country dynamics 7.7.2.2. Competitive scenario 7.7.2.3. Regulatory framework 7.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million) 7.7.3. Argentina 7.7.3.1. Key country dynamics 7.7.3.2. Competitive scenario 7.7.3.3. Regulatory framework 7.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million) 7.8. MEA 7.8.1. Market estimates and forecasts 2021 to 2033 (USD Million) 7.8.2. South Africa 7.8.2.1. Key country dynamics 7.8.2.2. Competitive scenario 7.8.2.3. Regulatory framework 7.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million) 7.8.3. Saudi Arabia 7.8.3.1. Key country dynamics 7.8.3.2. Competitive scenario 7.8.3.3. Regulatory framework 7.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) 7.8.4. UAE 7.8.4.1. Key country dynamics 7.8.4.2. Competitive scenario 7.8.4.3. Regulatory framework 7.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million) 7.8.5. Kuwait 7.8.5.1. Key country dynamics 7.8.5.2. Competitive scenario 7.8.5.3. Regulatory framework 7.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) Chapter 8. Competitive Landscape 8.1. Company/Competition Categorization 8.2. Strategy Mapping 8.3. Company Market Position Analysis, 2025 8.4. Company Profiles/Listing 8.4.1. Thermo Fisher Scientific, Inc. 8.4.1.1. Company overview 8.4.1.2. Financial performance 8.4.1.3. Product benchmarking 8.4.1.4. Strategic initiatives 8.4.2. Merck KGaA 8.4.2.1. Company overview 8.4.2.2. Financial performance 8.4.2.3. Product benchmarking 8.4.2.4. Strategic initiatives 8.4.3. OriGene Technologies Inc. 8.4.3.1. Company overview 8.4.3.2. Financial performance 8.4.3.3. Product benchmarking 8.4.3.4. Strategic initiatives 8.4.4. FinVector Oy 8.4.4.1. Company overview 8.4.4.2. Financial performance 8.4.4.3. Product benchmarking 8.4.4.4. Strategic initiatives 8.4.5. Sino Biological Inc. 8.4.5.1. Company overview 8.4.5.2. Financial performance 8.4.5.3. Product benchmarking 8.4.5.4. Strategic initiatives 8.4.6. Oxford Biomedica 8.4.6.1. Company overview 8.4.6.2. Financial performance 8.4.6.3. Product benchmarking 8.4.6.4. Strategic initiatives 8.4.7. Lonza 8.4.7.1. Company overview 8.4.7.2. Financial performance 8.4.7.3. Product benchmarking 8.4.7.4. Strategic initiatives 8.4.8. Vector Biolabs 8.4.8.1. Company overview 8.4.8.2. Financial performance 8.4.8.3. Product benchmarking 8.4.8.4. Strategic initiatives 8.4.9. Takara Bio Inc. 8.4.9.1. Company overview 8.4.9.2. Financial performance 8.4.9.3. Product benchmarking 8.4.9.4. Strategic initiatives 8.4.10. Sirion-Biotech GmbH (Revvity) 8.4.10.1. Company overview 8.4.10.2. Financial performance 8.4.10.3. Product benchmarking 8.4.10.4. Strategic initiatives List of Tables/GraphsList of TablesTable 1 List of abbreviation Table 2 Global lentiviral vector market, by region, 2021 - 2033 (USD Million) Table 3 Global lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 4 Global lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 5 Global lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 6 North America lentiviral vector market, by country, 2021 - 2033 (USD Million) Table 7 North America lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 8 North America lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 9 North America lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 10 U.S. lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 11 U.S. lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 12 U.S. lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 13 Canada lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 14 Canada lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 15 Canada lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 16 Mexico lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 17 Mexico lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 18 Mexico lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 19 Europe lentiviral vector market, by country, 2021 - 2033 (USD Million) Table 20 Europe lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 21 Europe lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 22 Europe lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 23 Germany lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 24 Germany lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 25 Germany lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 26 UK lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 27 UK lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 28 UK lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 29 France lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 30 France lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 31 France lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 32 Italy lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 33 Italy lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 34 Italy lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 35 Spain lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 36 Spain lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 37 Spain lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 38 Denmark lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 39 Denmark lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 40 Denmark lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 41 Sweden lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 42 Sweden lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 43 Sweden lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 44 Norway lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 45 Norway lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 46 Norway lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 47 Asia Pacific lentiviral vector market, by country, 2021 - 2033 (USD Million) Table 48 Asia Pacific lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 49 Asia Pacific lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 50 Asia Pacific lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 51 China lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 52 China lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 53 China lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 54 Japan lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 55 Japan lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 56 Japan lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 57 India lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 58 India lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 59 India lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 60 South Korea lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 61 South Korea lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 62 South Korea lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 63 Australia lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 64 Australia lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 65 Australia lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 66 Thailand lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 67 Thailand lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 68 Thailand lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 69 Latin America lentiviral vector market, by country, 2021 - 2033 (USD Million) Table 70 Latin America lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 71 Latin America lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 72 Latin America lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 73 Brazil lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 74 Brazil lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 75 Brazil lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 76 Argentina lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 77 Argentina lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 78 Argentina lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 79 MEA lentiviral vector market, by country, 2021 - 2033 (USD Million) Table 80 MEA lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 81 MEA lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 82 MEA lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 83 South Africa lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 84 South Africa lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 85 South Africa lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 86 Saudi Arabia lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 87 Saudi Arabia lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 88 Saudi Arabia lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 89 UAE lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 90 UAE lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 91 UAE lentiviral vector market, by end use, 2021 - 2033 (USD Million) Table 92 Kuwait lentiviral vector market, by product, 2021 - 2033 (USD Million) Table 93 Kuwait lentiviral vector market, by indication, 2021 - 2033 (USD Million) Table 94 Kuwait lentiviral vector market, by end use, 2021 - 2033 (USD Million)List of Figures Fig. 1 Market research process Fig. 2 Data triangulation techniques Fig. 3 Market formulation & validation Fig. 4 Lentiviral Vector market: Market outlook Fig. 5 Lentiviral Vector market: Segment outlook Fig. 6 Lentiviral Vector market: Competitive landscape outlook Fig. 7 Parent market outlook Fig. 8 Lentiviral Vector market driver impact Fig. 9 Lentiviral Vector market restraint impact Fig. 10 Lentiviral Vector market: Product outlook and key takeaways Fig. 11 Lentiviral Vector market: Product movement analysis Fig. 12 1st-generation market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 13 2nd-generation market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 14 3rd-generation market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 15 Lentiviral Vector market: Indication outlook and key takeaways Fig. 16 Lentiviral Vector market: Indication movement analysis Fig. 17 HIV market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 18 Β-thalassemia market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 19 X-linked adrenoleukodystrophy market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 20 Metachromatic leukodystrophy market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 21 Wiskott-aldrich syndrome market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 22 Lentiviral Vector market: End Use outlook and key takeaways Fig. 23 Lentiviral Vector market: End Use movement analysis market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 24 Pharmaceutical and biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 25 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 26 CROs & CMOs market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 27 Global Lentiviral Vector market: Regional outlook and key takeaways Fig. 28 Global Lentiviral Vector market: Regional movement analysis Fig. 29 North America market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 30 Key country dynamics Fig. 31 U.S. market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 32 Key country dynamics Fig. 33 Canada market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 34 Key country dynamics Fig. 35 Mexico market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 36 Europe market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 37 Key country dynamics Fig. 38 UK market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 39 Key country dynamics Fig. 40 Germany market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 41 Key country dynamics Fig. 42 France market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 43 Key country dynamics Fig. 44 Italy market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 45 Key country dynamics Fig. 46 Spain market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 47 Key country dynamics Fig. 48 Denmark market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 49 Key country dynamics Fig. 50 Sweden market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 51 Key country dynamics Fig. 52 Norway market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 53 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 54 Key country dynamics Fig. 55 China market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 56 Key country dynamics Fig. 57 Japan market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 58 Key country dynamics Fig. 59 India market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 60 Key country dynamics Fig. 61 Thailand market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 62 Key country dynamics Fig. 63 South Korea market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 64 Key country dynamics Fig. 65 Australia market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 66 Latin America market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 67 Key country dynamics Fig. 68 Brazil market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 69 Key country dynamics Fig. 70 Argentina market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 71 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 72 Key country dynamics Fig. 73 South Africa market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 74 Key country dynamics Fig. 75 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 76 Key country dynamics Fig. 77 UAE market estimates and forecasts, 2021 - 2033 (USD Million) Fig. 78 Key country dynamics Fig. 79 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（バイオ薬物）の最新刊レポート
Grand View Research社の 生物分野 での最新刊レポート
本レポートと同じKEY WORD（vector）の最新刊レポートよくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
